Matthew Dowd Image

Matthew Dowd

Founder and Managing Partner

Dowd Scheffel PLLC

Matthew Dowd is Founder and Managing Partner at Dowd Scheffel PLLC. He focuses his skills on complex appellate and trial litigation, with an emphasis on patent and intellectual property issues.  Through his years of practice, Mr. Dowd has successfully worked on numerous high-stakes and eclectic legal matters, focusing primarily on all stages of complex patent matters (AIA proceedings, litigation, prosecution, and counseling).  Mr. Dowd’s expertise and leadership are regularly consulted, as he is frequently asked to comment in the press on leading intellectual property issues.

Mr. Dowd has substantial experience with Hatch-Waxman litigation, including all stages of opinion analysis, litigation, and appeals.  His technical background in medicinal chemistry is ideally suited for litigating pharmaceutical patents.  He has represented clients in a range of trial forums for patent disputes, such as the Eastern District of Texas and the District of Delaware, as well as the Patent Trial and Appeal Board at the USPTO.

He has argued appeals before the U.S. Court of Appeals for the Federal Circuit, the Ninth Circuit, and the D.C. Circuit, with over fifteen appeals (and briefed numerous others) before the Federal Circuit and other courts involving issues such as patent law, Hatch-Waxman, administrative law, Fifth Amendment takings, contract claims, government employment issues, and criminal law.  Most recently, in 2018, Mr. Dowd was co-counsel with the Hon. Richard Posner (ret.) of U.S. Court of Appeals for the Seventh Circuit in an appeal before the U.S. Court of Appeals for the Fourth Circuit.

Recent Articles by Matthew Dowd

The CRISPR Battle Through the Lens of International Patent Harmonization

On Tuesday, May 7, the U.S. Court of Appeals for the Federal Circuit will hear argument in a long-awaited appeal addressing the inventorship of the Nobel Prize-winning CRISPR technology. The case is the latest in a continuing legal battle between two groups of innovators, each asserting patent rights to key aspects of the groundbreaking technology.

Juno v. Kite: A Rare Opportunity for the Supreme Court to Grant Rehearing

The patent world is trained on the upcoming Supreme Court Amgen v. Sanofi case. That case is the first time in over 75 years that the Supreme Court is evaluating the meaning and scope of the enablement requirement of 35 U.S.C. § 112. The case offers the Court an opportunity to correct a negative trend in enablement law that has made it more difficult to protect groundbreaking, pioneering inventions. Waiting in the wings, however, is an equally important Section 112 case: . There, the petitioner sought review on whether “the ‘written description of the invention’ [is] to be measured by the statutory standard of ‘in such full, clear, concise, and exact terms as to enable any person skilled in the art to make and use the same.’” As is apparent, Juno’s written description issue is highly intertwined with the Section 112 enablement issue in Amgen v. Sanofi.

Past Events with Matthew Dowd